Shashwat Sharad1,2

1 Center for Prostate Disease Research, Department of Surgery, Uniformed Services University and theWalter Reed National Military Medical Center, Bethesda, Maryland, USA

2 Henry Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA

\*Address all correspondence to: sharadshashwat@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**9**

*Antisense Therapy: An Overview*

[1] Kaczmarek JC, Kowalski PS,

[2] Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members. Clinical Cancer Research.

[3] Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Journal of Postdoctoral

[5] Bennett CF, Swayze E, Henry S, Geary R. Antisense oligonucleotide-based therapeutics. In: Templeton NS, editor. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. Boca Raton,

**References**

2017;**9**(1):60

2007;**13**:7264-7270

Research. 2016;**4**(7):35-50

[4] Ling H. Non-coding RNAs: Therapeutic strategies and delivery systems. Advances in Experimental Medicine and Biology. 2016;**937**:229-237

FL: CRC Press; 2015. pp. 467-492

2017;**57**:81-105

[6] Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. Pharmacology of antisense drugs. Annual Review of Pharmacology and Toxicology.

[7] Farooqi AA, Rehman ZU, Muntane J. Antisense therapeutics in oncology: Current status. OncoTargets and Therapy. 2014;**7**:2035-2042

[8] Bennett CF, Swayze EE. RNA targeting therapeutics: Molecular

oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology.

[9] Zhou Y, Zhang C, Liang W. Development of RNAi technology for

mechanisms of antisense

2010;**50**:259-293

*DOI: http://dx.doi.org/10.5772/intechopen.86867*

Anderson DG. Advances in the delivery of RNA therapeutics: From concept to clinical reality. Genome Medicine.

targeted therapy—A track of siRNAbased agents to RNAi therapeutics. Journal of Controlled Release.

[10] Stein CA, Castanotto D. FDAapproved oligonucleotide therapies

[11] Piascik P. Fomiversen sodium approved to treat CMV retinitis. Journal

of the American Pharmaceutical Association. 1999;**39**:84-85

[12] Krishna M. From petunias to the present- a review of oligonucleotide therapy. Journal of Clinical Epigenetics.

[13] Zielinski R, Chi KN. Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. Future Oncology.

[14] Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, et al.

in lymphoma and lung cancer. Science Translational Medicine.

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity

[15] Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, et al. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamideresistant prostate cancer cell growth. Clinical Cancer Research.

[16] Rader DJ, Kastelein JJ. Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous

familial hypercholesterolemia. Circulation. 2014;**129**:1022-1032

in 2017. Molecular Therapy. 2017;**25**(5):1069-1075

2014;**193**:270-281

2017;**3**(4):38

2012;**8**:1239-1251

2015;**7**:314ra185

2015;**21**:1675-1687
